Tachibana Aaron sold $480K of PSNL

Person has agreed to a merger with Tempus, becoming a wholly owned subsidiary. The HSR waiting period expired on Oct 2, 2026. The deal requires stockholder approval and other conditions. Tempus filed relevant documents with the SEC.

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on July 20, 2026, Personalis, Inc., a Delaware corporation (“ Personalis ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Tempus AI, Inc., a Nevada corporation (“ Tempus ” or “ Par

Personalis (PSNL) stock fell 2.8% after BTIG downgraded it to Neutral, removing the $16.25 price target. The analyst believes the Tempus AI acquisition will close at the agreed price, with little chance of improvement. BTIG also concluded that the board prioritized deal speed over a higher bid, despite interest from Merck. The S&P 500 and other indices rose, but Personalis' decline was stock-specific.

Personalis CFO Aaron Tachibana sold 2,931 shares at $16.22 each, totaling $47,540, to cover tax obligations. Tempus AI agreed to acquire Personalis for $1.5B, offering $16.25 per share, a 6% premium. Needham downgraded Personalis to Hold, raised its target to $17, and reiterated a Buy rating for Tempus AI with a $75 target. Personalis received UK regulatory clearance for its NeXT Personal Dx test.

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.